Trials / Completed
CompletedNCT03343665
Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- St. Petersburg State Pavlov Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A phase I/II trial to evaluate the safety and efficacy of nivolumab at the fixed dose 40 mg in patients with relapsed or refractory Hodgkins lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab 40 mg in 4 ml Injection | 40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2019-12-20
- Completion
- 2019-12-20
- First posted
- 2017-11-17
- Last updated
- 2020-01-23
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT03343665. Inclusion in this directory is not an endorsement.